Rosalind group reports 5.5% stake in Cellectar
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cellectar Biosciences, Inc. received an amended Schedule 13G showing that investment entities associated with Rosalind Advisors, Inc. report beneficial ownership tied to up to 247,715 common shares, representing 5.5% of the class, as of an event date of 12/31/2025.
The percentage is based on 4,240,134 common shares outstanding as of November 10, 2025. The filing explains that this figure reflects shares issuable upon full conversion of preferred stock and exercise of warrants, but actual ownership is contractually capped by blockers limiting conversions above 9.99% and warrant exercises above 4.99% of outstanding common stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Cellectar Biosciences (CLRB) does the Rosalind group report?
Which entities are included in the Rosalind group in this Cellectar (CLRB) Schedule 13G/A?
How is the 5.5% Cellectar (CLRB) ownership percentage calculated in the filing?
What are the ownership blockers described in the Cellectar (CLRB) Schedule 13G/A?
Do Rosalind Advisors and Steven Salamon claim full beneficial ownership of Cellectar (CLRB) shares?
Does the Rosalind group indicate any intent to influence control of Cellectar Biosciences (CLRB)?
AI-generated analysis. How Rhea-AI works. Not financial advice.